IL-10 Inhibits LPS-Induced Production of Type I IFN
| Treatment . | Protection (%) . | Inhibition (%) . |
|---|---|---|
| Experiment no. 1 | ||
| None | 0 | NA |
| LPS | 51.3 | 0 |
| LPS + IL-10 | 12.8 | 75 |
| Experiment no. 2 | ||
| None | 0 | NA |
| LPS | 20.1 | 0 |
| LPS + IL-10 | 5.8 | 71 |
| Treatment . | Protection (%) . | Inhibition (%) . |
|---|---|---|
| Experiment no. 1 | ||
| None | 0 | NA |
| LPS | 51.3 | 0 |
| LPS + IL-10 | 12.8 | 75 |
| Experiment no. 2 | ||
| None | 0 | NA |
| LPS | 20.1 | 0 |
| LPS + IL-10 | 5.8 | 71 |
TG-elicited peritoneal macrophages (1 × 107) were stimulated with LPS (10 ng/mL) without or with IL-10 (25 ng/mL) for 4 hours. Supernatants were harvested and used to pretreat cultures of MEF cells for 24 hours before infection with EMC virus at an MOI of 2. Control cultures were treated with supernatant but not infected with virus. After 24 hours, MEF cell viability was assayed. The percentage of protection was calculated as described in Materials and Methods. Antiviral activity was completely inhibited by anti-IFNα/β antibody (data not shown).
Abbreviation: NA, not applicable.